7-[3-(3-hydroxy-4,4-dimethyl-octyl)-2,5-dioxo-imidazolidin-4-yl]-heptanoic acid | 75246-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 7-[3-(3-hydroxy-4,4-dimethyl-octyl)-2,5-dioxo-imidazolidin-4-yl]-heptanoic acid
• 英文别名: 7-[3-(3-Hydroxy-4,4-dimethyloctyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
• CAS: 75246-43-4
• 化学式: C₂₀H₃₆N₂O₅
• 分子量: 384.516
• InChiKey: OBWREGPIKZZJLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Hydantoins and thiohydantoins, method for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0003410A1

  公开（公告）日：1979-08-08

  Compounds of the formula 1: wherein: X is 0 or S; R, is hydrogen, or C02R1 represents an ester group in which the R1 moiety contains from 1 - 12 carbon atoms; R2 is hydrogen or C1-4 alkyl; R4 is C7-9 alkyl, C3-8 cycloalkyl or C3.8 cycloalkyl-C1-6 alkyl; or R2 and R4 taken with the carbon atom to which they are joined represent a C5-8 cycloalkyl group; and R5 is C1-6 alkyl; and salts thereof, having similar activity to natural prostaglandins, a process for their preparation, intermediates useful in that process and pharmaceutical compositions containing them.

  式 1 的化合物： 其中 X 是 0 或 S； R 是氢，或 C02R1 代表酯基，其中 R1 分子含有 1-12 个碳原子； R2 是氢或 C1-4 烷基； R4 是 C7-9 烷基、C3-8 环烷基或 C3.8 环烷基-C1-6 烷基；或 R2 和 R4 与它们连接的碳原子一起代表 C5-8 环烷基；以及 R5是C1-6烷基；及其盐类，具有与天然前列腺素相似的活性，制备它们的工艺，在该工艺中有用的中间体，以及含有它们的药物组合物。
• Pharmaceutical combinations including hydantoin derivatives, pharmaceutical formulations containing the combinations and methods of making the formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0011828A1

  公开（公告）日：1980-06-11

  Combinations of an active compound selected from the class outstanding of hydantoin and thiohydantoin derivatives and their salts together with a phosphodiesterase inhibitor. Such combinations have pharmacological effects related to those of the active compound alone but these effects (other than vasodilatory effects) are potentiated by the phosphodiesterase inhibitor whilst the vasodilatory effect is not so potentiated. The combination may be used in medicine either along or in a formulation, for example in the treatment of thrombosis.

  选自海因和硫代海因衍生物及其盐类的活性化合物与磷酸二酯酶抑制剂的复方制剂。这种复方制剂的药理作用与单独使用活性化合物的药理作用相同，但磷酸二酯酶抑制剂可增强这些作用（除血管扩张作用外），而血管扩张作用则不受影响。这种复方制剂可单独或以制剂的形式用于医药领域，例如用于治疗血栓形成。
• Hydantoin derivatives, their preparation and pharmaceutical compositions
  申请人：BEECHAM GROUP PLC

  公开号：EP0014076B1

  公开（公告）日：1983-02-09
• US4204068A
  申请人：——

  公开号：US4204068A

  公开（公告）日：1980-05-20
• US4262128A
  申请人：——

  公开号：US4262128A

  公开（公告）日：1981-04-14